Article citationsMore>>

Yi, Z.M., Wen, C., Cai, T., Xu, L., Zhong, X.L., et al. (2018) Levetiracetam for Epilepsy: An Evidence Map of Efficacy, Safety and Economic Profiles. Neuropsychiatric Disease and Treatment, 15, 1-19.
https://doi.org/10.2147/NDT.S181886

has been cited by the following article:

• TITLE: Acute Kidney Injury with Levetiracetam in Patient with Epilepsy: A Case Report

  AUTHORS: Khalid Al-Quliti, Rakan Maher Alhujeily

  KEYWORDS: Acute Kidney Injury, Epilepsy, Levetiracetam

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.11 No.3, March 8, 2022

  ABSTRACT: Epilepsy is a common neurological disorder in neurology clinic. Levetiracetam is considered as one of common antiepileptic drugs used to manage epilepsy with good efficacy and tolerability profile. It is renally excreted and not depending on the cytochrome p450. It has adverse effects reported as somnolence, headaches, dizziness, depression and anxiety. Also, it was reported that levetiracetam can cause Acute kidney injury (AKI), renal profile disturbance, that may be related to its way of excretion and possible nephrotoxicity especially with high loading dose. We are reporting a young female patient with epilepsy presented to hospital with status epileptcus and started on loading dose of levetiracetam 3 grams and then maintenance dose of 1 gram twice daily seizure were controlled but she developed acute kidney injury that improved after discontinue leveriracetam and medical management without renal dialysis and discharged home in stable condition. Physician and health care providers should be aware of such rare adverse reaction and available management options for better patient care and outcome.